The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of the single-agent CDK4/6 inhibitor LEE011 in pts with advanced solid tumors and lymphomas.
Jeffrey R. Infante
No relevant relationships to disclose
Geoffrey Shapiro
Research Funding - Funding to Dana Farber for the conduct of the study
Petronella Witteveen
No relevant relationships to disclose
John F. Gerecitano
No relevant relationships to disclose
Vincent Ribrag
No relevant relationships to disclose
Rashmi Chugh
Research Funding - Novartis
Isra Issa
Employment or Leadership Position - Novartis
Abhijit Chakraborty
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Alessandro Matano
Employment or Leadership Position - Novartis
Xumei Zhao
Employment or Leadership Position - Novartis
Sudha Parasuraman
Employment or Leadership Position - Novartis
Stock Ownership - Novartis
Phillipe Cassier
Consultant or Advisory Role - SERVIER
Honoraria - GlaxoSmithKline; Novartis
Research Funding - Novartis; Roche
Other Remuneration - Novartis; SERVIER